



DePuy ASR Hip Implant Recall

Introduction

On the 26th August 2010 DePuy Orthopaedics Inc. announced a worldwide recall of its ASR Hip Implant, which first came to market in 2003. Over 3,500 patients underwent DePuy hip implant surgeries in fourteen private and sixteen public hospitals in Ireland.

At the end of 2010 it was estimated that the failure rate for the DePuy ASR hip implant stood at 13% after five years. It is now projected that 49% of all DePuy ASR hip implants could fail within six years, so 1,700 people in Ireland alone may require the revision surgery.

What symptoms are patients of defective implants experiencing?

Those patients who have been implanted with defective DePuy hip implants may have pain, loss of mobility and in some cases, soft tissue injuries to muscles and nerves in the area of their hip.

What is Metallosis/metal poisoning?

In addition to the mechanical failure of the device, metal poisoning is a serious concern. This is due to the metal on metal contact between the ball and the socket of the implant, which can cause metallosis (body reacts to metal.) Metallosis can cause inflammation around the joint, tissue damage and bone damage.

Are there risks associated with further surgery for patients?

Many patients require further surgery exposing them to all the risks associated with such major surgery including infection, adverse reaction to anaesthesia and a loss of opportunity for future hip replacements, a particular concern for the young and more active for whom these DePuy ASR products were specifically marketed.

At a recent DePuy Hip Recall Conference, which Lynch Solicitors hosted, DePuy patients learned that there is a very slow recovery following revision surgery because metal debris stays in the tissues for some time after the metallic joint has been removed and the body can still react creating inflammation. The pain does, however, seem to improve over time.

